scholarly journals ACUTE ASTHMA, PROGNOSIS, AND TREATMENT

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Khaled Hassan
Keyword(s):  
Mortality Rate ◽  
Acute Asthma ◽  
Signs And Symptoms ◽  
Chronic Inflammatory Disease ◽  
Online Searching ◽  
Major Health Problem ◽  
Oxygen Administration ◽  
Asthma Exacerbations ◽  
Fatal Asthma ◽  
Keywords Asthma

Background: Asthma is a major health problem affecting all ages that increase the mortality rate worldwide. Early detection of its signs and symptoms are essential to control and maintain the disease and effective treatments are administrated, such as; ?-agonists and corticosteroids. The current review is about acute asthma, prognosis, and treatment. Methods: Scientific articles that linked to the present topic were obtained using an online searching process. The searching process included different scientific websites such as Google Scholar and PubMed. We obtained 16 articles that matched with the current subject and written in English. Of those 16 articles, 4 were excluded as they published before 2000, or mayn’t focusing on the present topic, or written in a language other than English; therefore, only 12 papers were included, and they were published till 2020. Results: Articles were selected according to the inclusion criteria that we selected, and then the discussion of the subject was performed under the main titles. Conclusion: Asthma is one of the most chronic inflammatory disease that increased the mortality rate worldwide. Asthma could affect 300 million individuals and account for one death among 250 death cases. All patients admitted with asthma exacerbation should be assessed promptly through detecting and recognition worsening signs and symptoms. The initial treatment includes oxygen administration, Short-acting ?-agonist, and systematic corticosteroids. Decreasing the severity of asthma exacerbations by improving daily therapy for asthma, controlling environmental triggers, and increasing patient education toward asthma risks and how they recognize its symptoms and seek for health care help.    Keywords: Asthma exacerbations, ?-agonist, corticosteroids, differential diagnosis, fatal and non-fatal asthma.

scholarly journals Acute asthma exacerbations: an overview

2014 ◽  
Vol 5 (3) ◽  
pp. 135-146
Author(s):  
Domenico Lorenzo Urso
Keyword(s):  
Inflammatory Disease ◽  
Acute Asthma ◽  
Airflow Obstruction ◽  
Chronic Inflammatory Disease ◽  
Severe Hypoxemia ◽  
Asthma Exacerbations ◽  
Rapid Reversal ◽  
Life Threatening ◽  
Acute Asthma Exacerbations ◽  
Risk Of Relapse

Asthma is a chronic inflammatory disease of the airways. All patient with asthma are at risk of having exacerbations characterized by worsening symptoms, airflow obstruction, and an increased requirement for rescue bronchodilators. Asthma exacerbations can be classified as mild, moderate, severe, or life threatening. The goals of treatment are correction of severe hypoxemia, rapid reversal of airflow obstruction, and reduction of the risk of relapse.

Identifying An At-Risk Population of Children With Recurrent Near-Fatal Asthma Exacerbations

2010 ◽  
Vol 47 (4) ◽  
pp. 460-464 ◽  
Author(s):  
Christopher L. Carroll ◽  
Burcin Uygungil ◽  
Aaron R. Zucker ◽  
Craig M. Schramm
Keyword(s):  
At Risk ◽  
Risk Population ◽  
Asthma Exacerbations ◽  
Fatal Asthma ◽  
Near Fatal Asthma

Survey of physicians’ attitudes toward the use of magnesium sulfate for acute asthma exacerbations in Turkey

2016 ◽  
Vol 53 (5) ◽  
pp. 525-531 ◽  
Author(s):  
Ayşe Baççıoğlu ◽  
Arzu Bakırtaş ◽  
Ferda Öner Erkekol ◽  
Ömer Kalaycı ◽  
Sevim Bavbek
Keyword(s):  
Magnesium Sulfate ◽  
Acute Asthma ◽  
Asthma Exacerbations ◽  
Acute Asthma Exacerbations

Oral Dexamethasone to Control Wheezing in Children at an Outpatient Clinic

2018 ◽  
Vol 58 (2) ◽  
pp. 151-158 ◽  
Author(s):  
Angela S. Volk ◽  
Stephanie A. Marton ◽  
Brittany S. Richardson ◽  
Luis Rauda ◽  
Heidi L. Schwarzwald ◽  
...  
Keyword(s):  
Hospital Admissions ◽  
Acute Asthma ◽  
Hospital Setting ◽  
Retrospective Chart Review ◽  
Office Visit ◽  
Asthma Exacerbations ◽  
Oral Dexamethasone ◽  
Cost Effective Treatment ◽  
Ed Visits ◽  
Acute Asthma Exacerbations

Asthma, a chronic childhood disease, has resulted in increased emergency department (ED) visits with high costs. Many asthma ED visits are nonemergent and could be treated in outpatient clinics. Literature has concluded that a 2-day course of oral dexamethasone has comparable outcomes to a 5-day course of prednisone in the ED and hospital setting. A retrospective chart review was performed on children requiring in-house treatment with a corticosteroid (dexamethasone n = 23, prednisone n = 40) for acute asthma exacerbations at an ambulatory medical home. The rates of hospital admissions, ED visits, and symptom follow-up were similar between the 2 groups ( P > .05). The cost for a course of dexamethasone was US$1.28 versus US$16.20 for prednisolone. The average cost for an asthma exacerbation office visit was US$79.89 compared with US$3113.28 for an ED visit. A 2-day course of oral dexamethasone appears to be a promising clinical and cost-effective treatment for acute asthma exacerbations at the primary care level.

scholarly journals Membandingkan Kejadian Gangguan Gastrointestinal Penggunaan Aminofilin dan Salbutamol pada Pasien Eksaserbasi Asma di Surabaya

2019 ◽  
Vol 1 (1) ◽  
pp. 1-10
Author(s):  
Amelia Lorensia ◽  
Zullies Ikawati ◽  
Tri Murti Andayani ◽  
Daniel Maranatha ◽  
Rizki Amalia
Keyword(s):  
Asthma Exacerbation ◽  
Acute Asthma ◽  
Shortness Of Breath ◽  
Drug Reactions ◽  
Asthma Exacerbations ◽  
Gastrointestinal Problems ◽  
Asthma Patients ◽  
Quasi Experimental ◽  
Expiratory Air ◽  
Over Time

Abstract—Asthma is a heterogeneous disease, which is characterized by inflammation of the respiratory tract with respiratory classification such as wheezing, shortness of breath, distress in the chest and coughing over time and intensity with variations in expiratory air flow. In Indonesia the prevalence of asthma is uncertain, it is not estimated that 2-5% of Indonesia's population has asthma. The main objective of this study is to study gastrointestinal-related cases of the use of aminophylline and salbutamol in asthma exacerbation patients in hospitals in Surabaya and also to discuss gastrointestinal problems related to ADRs (Bad Drug Reactions) using the use of aminophylline and salbutamol on Naranjo scale. In this study using the Quasi Experimental method. This research was conducted in October 2014 to February 2015. The results of the study of 7 samples obtained 14.29% using ADR from the use of aminophylline and from 13 patients in the use of salbutamol was not found ADR can be used in accordance with the existing salbutamol in patients with asthma exacerbations at hospitals in Surabaya. The general benefits of this study are useful in monitoring the treatment of acute asthma patients who need salbutamol and theophylline therapy so as to reduce the incidence of ADR. Abstrak—Asma merupakan penyakit heterogen, yang ditandai dengan peradangan saluran napas kronis dengan disertai riwayat gejala pernapasan seperti mengi, sesak napas, rasa tertekan di dada dan batuk dari waktu ke waktu dan intensitas dengan variasi keterbatasan aliran udara ekspirasi. Di Indonesia prevalensi asma belum diketahui secara pasti, namun diperkirakan 2-5 % penduduk Indonesia menderita asma. Tujuan utama penelitian ini adalah untuk mengetahui perbedaan kejadian gangguan gastrointestinal pada penggunaan aminofilin dan salbutamol pada pasien eksaserbasi asma di Rumah Sakit di Surabaya serta mengetahui kejadian gangguan gastrointestinal terkait ADRs (Adverse Drug Reaction) akibat penggunaan aminofilin dan salbutamol berdasarkan penilaian Naranjo scale. Pada penelitian ini menggunakan metode Quasi Eksperimental. Penelitian ini dilakukan pada bulan Oktober 2014 sampai Februari 2015. Hasil penelitian dari 7 sampel diperoleh 14,29% mengalami ADR dari penggunaan aminofilin dan dari 13 pasien pada pengguanaan salbutamol tidak ditemukan ADR sehingga dapat disimpulkan bahwa tidak ada perbedaan kejadian gangguan gastrointestinal pada penggunaan aminofilin dan salbutamol pada pasien eksaserbasi asma di Rumah Sakit di Surabaya. Manfaat umum dari penelitian ini adalah berguna dalam monitoring pengobatan pasien asma akut terutama yang mendapat terapi salbutamol dan teofilin sehingga dapat mengurangi angka kejadian ADR.

The Utility of Albuterol Nebulized With Heliox during Acute Asthma Exacerbations

2003 ◽  
Vol 41 (5) ◽  
pp. 766-767
Author(s):  
JP Kress ◽  
I Noth ◽  
BK Gehlbach ◽  
RK Cydulka
Keyword(s):  
Acute Asthma ◽  
Asthma Exacerbations ◽  
Acute Asthma Exacerbations

Brain Tumors during the First Twenty-four Months of Life

Neurosurgery ◽  
1985 ◽  
Vol 17 (6) ◽  
pp. 913-919 ◽  
Author(s):  
Tadanori Tomita ◽  
David G. McLone
Keyword(s):  
Mortality Rate ◽  
Brain Tumors ◽  
Choroid Plexus Papilloma ◽  
Signs And Symptoms ◽  
Tumor Location ◽  
Surgical Mortality ◽  
Malignant Astrocytomas ◽  
Suprasellar Region ◽  
4Th Ventricle ◽  
Common Histological Type

Abstract One hundred patients with brain tumors were diagnosed and treated during the first 24 months of life. They represent 16% of 608 children with brain tumors treated from 1952 through 1984. The most common histological type of brain tumors during the first 24 months are benign astrocytoma, medulloblastoma, and choroid plexus papilloma. The tumor location is distributed relatively evenly among the cerebellum and the 4th ventricle, the cerebral hemisphere (including the lateral ventricle), and the suprasellar region and 3rd ventricle. The chief presenting signs and symptoms are a full fontanelle, macrocephaly, changes of behavior, and delayed developmental milestones. Localizing signs are infrequent. Ninety-two patients underwent craniotomy with a one-month surgical mortality rate of 12%. The surgical mortality rate was 5.6% among 36 recent patients diagnosed by computed tomography. The 5-year survival rate is 41% in the patients younger than 12 months and 74% in patients diagnosed during the 2nd year of life. This study indicates the validity of Collins' rule for medulloblastomas during the first 24 months of life, but not for benign or malignant astrocytomas.

Sign in / Sign up

Export Citation Format

Share Document